^
Association details:
| Biomarker: | EGFR C797S + EGFR T790M + EGFR L858R |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | CH7233163 (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 5689: CH7233163, a mutant-selective EGFR inhibitor, overcomes osimertinib resistant EGFR-T790M/C797S
Published date:
05/15/2020
Excerpt:
In this study, we identified CH7233163, a novel EGFR TKI, capable of overcoming the EGFR triple-mutation. CH7233163 inhibited preferentially enzymatic activity of EGFR triple-mutation, and showed potent antitumor activity against the tumor with EGFR triple-mutation in vitro and in vivo.
DOI:
10.1158/1538-7445.AM2020-5689
